Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection

Blood. 2004 Jun 1;103(11):4373-4. doi: 10.1182/blood-2004-02-0583.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents, Alkylating / adverse effects*
  • Graft Rejection / drug therapy*
  • Graft Rejection / pathology
  • Granulocyte Precursor Cells / drug effects
  • Hematologic Diseases / therapy
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Melphalan / adverse effects*
  • Stem Cell Transplantation
  • Transplantation Conditioning / adverse effects
  • Vidarabine / adverse effects*
  • Vidarabine / analogs & derivatives*

Substances

  • Antineoplastic Agents, Alkylating
  • Immunosuppressive Agents
  • Vidarabine
  • fludarabine
  • Melphalan